These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 3037449)

  • 1. Evidence that neurokinin A (substance K) neurons project from the striatum to the substantia nigra in rats.
    Nagashima A; Takano Y; Masui H; Kamiya H
    Neurosci Lett; 1987 Jun; 77(1):103-8. PubMed ID: 3037449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depletion in substance P- and neurokinin A-like immunoreactivity in substantia nigra after ibotenate-induced lesions of striatum.
    Arai H; Sirinathsinghji DJ; Emson PC
    Neurosci Res; 1987 Dec; 5(2):167-71. PubMed ID: 2448711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of GABA and L-glutamic acid on the potassium-evoked in vitro release of substance P- and neurokinin A-like immunoreactivities are different in the rat striatum and substantia nigra.
    Humpel C; Saria A
    Neurosci Lett; 1989 Oct; 105(1-2):159-63. PubMed ID: 2484728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopaminergic regulation of tachykinin metabolism in the striatonigral pathway.
    Li SJ; Sivam SP; McGinty JF; Huang YS; Hong JS
    J Pharmacol Exp Ther; 1987 Nov; 243(2):792-8. PubMed ID: 2445959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroleptic treatment induces region-specific changes in levels of neurokinin A and substance P in rat brain.
    Lindefors N; Brodin E; Ungerstedt U
    Neuropeptides; 1986 Apr; 7(3):265-80. PubMed ID: 2423911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo detection of immunoreactive neurokinin A release within rat substantia nigra and its dependency on a dopaminergic input.
    Furmidge LJ; Duggan AW; Arbuthnott GW
    Brain Res; 1995 May; 679(2):241-8. PubMed ID: 7633884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of responses by striatonigral substance P and neurokinin A systems to methamphetamine treatment.
    Hanson GR; Letter AA; Merchant K; Gibb JW
    Peptides; 1986; 7(6):983-7. PubMed ID: 2436197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurokinin A and substance P in striato-nigral neurons in rat brain.
    Lindefors N; Brodin E; Ungerstedt U
    Neuropeptides; 1986; 8(2):127-32. PubMed ID: 2429229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tachykinin multiplicity in rat central nervous system as studied using antisera raised against substance P and neurokinin A.
    Brodin E; Lindefors N; Dalsgaard CJ; Theodorsson-Norheim E; Rosell S
    Regul Pept; 1986 Feb; 13(3-4):253-72. PubMed ID: 2422706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regional distribution of neuropeptide K and other tachykinins (neurokinin A, neurokinin B and substance P) in rat central nervous system.
    Arai H; Emson PC
    Brain Res; 1986 Dec; 399(2):240-9. PubMed ID: 2435360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The localization and characterization of substance P and substance K in striatonigral neurons.
    Lee JM; McLean S; Maggio JE; Zamir N; Roth RH; Eskay RL; Bannon MJ
    Brain Res; 1986 Apr; 371(1):152-4. PubMed ID: 2423184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Injection of tachykinins and selective neurokinin receptor ligands into the substantia nigra reticulata increases striatal dopamine and 5-hydroxytryptamine metabolism.
    Humpel C; Saria A; Regoli D
    Eur J Pharmacol; 1991 Mar; 195(1):107-14. PubMed ID: 1712305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tachykinins (substance P, neurokinin A, neuropeptide K) and the carcinoid flush.
    Conlon JM; Deacon CF; Richter G; Stöckmann F; Creutzfeldt W
    Scand J Gastroenterol; 1987 Jan; 22(1):97-105. PubMed ID: 2882598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topographical organization of the striatonigral pathway revealed by anterograde and retrograde neuroanatomical tracing techniques.
    Tulloch IF; Arbuthnott GW; Wright AK
    J Anat; 1978 Oct; 127(Pt 2):425-41. PubMed ID: 721701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement and partial characterization of the multiple forms of neurokinin A-like immunoreactivity in carcinoid tumours.
    Conlon JM; Deacon CF; Richter G; Schmidt WE; Stöckmann F; Creutzfeldt W
    Regul Pept; 1986 Jan; 13(2):183-96. PubMed ID: 3006157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organization of striatopallidal, striatonigral, and nigrostriatal projections in the macaque.
    Hedreen JC; DeLong MR
    J Comp Neurol; 1991 Feb; 304(4):569-95. PubMed ID: 2013650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tachykinin recovery during postmortem bronchoconstriction in guinea pig lungs.
    Martins MA; Shore SA; Drazen JM
    J Appl Physiol (1985); 1991 Mar; 70(3):1215-9. PubMed ID: 1709633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution and localization of neurokinin A-like immunoreactivity and neurokinin B-like immunoreactivity in rat peripheral tissue.
    Tateishi K; Kishimoto S; Kobayashi H; Kobuke K; Matsuoka Y
    Regul Pept; 1990 Oct; 30(3):193-200. PubMed ID: 2175441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subchronic haloperidol treatment decreases the in vivo release of tachykinins in rat substantia nigra.
    Lindefors N; Brodin E; Ungerstedt U
    Eur J Pharmacol; 1989 Feb; 161(1):95-8. PubMed ID: 2470596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Collateral projections from the substantia nigra to the cingulate cortex and striatum in the rat.
    Takada M; Hattori T
    Brain Res; 1986 Aug; 380(2):331-5. PubMed ID: 3756484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.